Cancer etiology is influenced by alterations in protein synthesis which are not fully understood. In this study, we took a novel approach to investigate the role of the eukaryotic translation initiation factor eIF5A in human cervical cancers where it is widely overexpressed. eIF5A contains the distinctive amino acid hypusine, which is formed by a post-translational modification event requiring deoxyhypusine hydroxylase (DOHH), an enzyme that can be inhibited by the drugs ciclopirox and deferiprone. We found that proliferation of cervical cancer cells could be blocked by DOHH inhibition with either of these pharmacological agents, as well as by RNAi-mediated silencing of eIF5A, DOHH or other enzymes in the hypusine pathway. Proteomic and RNA analyses in HeLa cervical cancer cells identified two groups of proteins in addition to eIF5A that were coordinately affected by ciclopirox and deferiprone. Group 1 proteins (HSP27, NM23
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Cancer etiology is influenced by alterations in protein synthesis which are not fully understood. In this study, we took a novel approach to investigate the role of the eukaryotic translation initiation factor eIF5A in human cervical cancers where it is widely overexpressed. eIF5A contains the distinctive amino acid hypusine, which is formed by a post-translational modification event requiring deoxyhypusine hydroxylase (DOHH), an enzyme that can be inhibited by the drugs ciclopirox and deferiprone. We found that proliferation of cervical cancer cells could be blocked by DOHH inhibition with either of these pharmacological agents, as well as by RNAi-mediated silencing of eIF5A, DOHH or other enzymes in the hypusine pathway. Proteomic and RNA analyses in HeLa cervical cancer cells identified two groups of proteins in addition to eIF5A that were coordinately affected by ciclopirox and deferiprone. Group 1 proteins (HSP27, NM23
and DJ-1) were downregulated at the translational level, whereas Group 2 proteins (TrpRS and PRDX2) were upregulated at the mRNA level. Further investigations of Hsp27 control confirmed that eIF5A and DOHH were required for its expression in cervical cancer cells and for regulation of its key targets IκB and NFκB there. Our results argue that mature eIF5A controls a translational network of cancer-driving genes, termed the eIF5A regulon, at the levels of mRNA abundance and translation. In coordinating cell proliferation, the eIF5A regulon can be modulated by drugs such as ciclopirox or deferiprone which might be repositioned to control cancer cell growth.
Precis: Findings suggest a mechanistic rationale to immediately reposition two approved drugs for cancer treatment, offering a low-risk clinical opportunity to evaluate new therapeutic modalities for cancer treatment.
Introduction
Despite advances in detection and prevention, cervical cancer remains the third most frequently diagnosed female cancer worldwide, with an estimated 275,000 deaths in 2008 (1) . For the United States, the National Cancer Institute estimated that over 12,000 new cases will be diagnosed in 2013, and that every third patient with this diagnosis will die despite state-of-the-art treatment. The identification of novel targets in cancer cells and the analysis of the molecular response to their suppression will promote the rational development of novel therapeutic modalities.
Translation, a key process in the gene expression pathway, is often dysregulated in cancer (2) . A strong correlation has been established between cancer and overexpression of the eukaryotic initiation factor 5A (eIF5A), which functions in protein synthesis (3) . Humans have two eIF5A isoforms: eIF5A1, expressed in many normal tissues, and eIF5A2, which enjoys more limited expression and distribution. Elevated levels of both isoforms characterize a variety of cancers and tumor-derived cell lines, and accumulating evidence links eIF5A to cell proliferation, cancer progression, invasiveness, metastasis and poor clinical prognosis (3, 4) .
Both isoforms carry the amino acid hypusine, which is apparently unique to eIF5A and essential for many (if not all) of its functions (3) . Hypusine is formed posttranslationally in sequential reactions catalyzed by two dedicated enzymes, deoxyhypusine synthase (DHS) and deoxyhypusine hydroxylase (DOHH) (Fig. 1A) . The singularity of this pathway presents attractive targets for drug development and cancer therapy (5).
The involvement of DOHH in cell cycle progression was recognized early (6) , and specific inhibitors were characterized (7). Of particular interest are two drugs that inhibit DOHH and hypusine formation at clinically relevant concentrations: ciclopirox (CPX), a topical antifungal (8) , and deferiprone (DEF), used to treat transfusional iron-overload such as in thalassemia (9) . Both drugs block cell proliferation and display anti-neoplastic potential. Thus CPX has been shown to inhibit the proliferation of cells in culture (10) (11) (12) and of breast cancer and myeloma xenograft growth in mice (11) (12) (13) . CPX also inhibits angiogenesis and lymphangiogenesis in established culture models (10, 14) . DEF inhibits the growth of HeLa cells derived from cervical carcinoma as well as other cancer cell lines (15) , and its analog mimosine slows the growth of subcutaneous lung and pancreatic cancer xenografts in mice (16) . The DHS substrate analog GC7 (Fig.   1A ) also impairs cancer cell growth, for example of glioblastoma cells (17) .
This study addresses the relationship between eIF5A, hypusine and gene expression in cervical cancer, and identifies cellular protein targets of the drugs CPX and DEF. We show that mature, hypusyl-eIF5A1 is highly expressed in proliferating cervical cancer tissue, of both the squamous cell and adenocarcinoma types, and in adenocarcinoma-derived HeLa cells. Cell proliferation was inhibited, and morphological changes occurred, after treatment with the drugs or eIF5A silencing. We devised a proteomic approach (Fig. 1B) to identify proteins that are regulated by both CPX and DEF using HeLa cells as a model. Five proteins, in addition to mature eIF5A itself, were identified whose synthesis and accumulation were coordinately affected by these drugs.
The proteins play key roles in cancer cell proliferation, survival and metastasis, and fall into two groups. Group 1 proteins were down-regulated by the drugs at the translational level, whereas Group 2 proteins were up-regulated at the mRNA level. The Group 1 protein Hsp27, a molecular chaperone, is a cancer biomarker and potential target for cancer therapy (18) . RNA interference experiments demonstrated that hypusyl-eIF5A is required for Hsp27 synthesis and modulates transcription via nuclear factor κB (NFκB).
Our data suggest that mature eIF5A1 regulates the expression of a set of genes, designated the eIF5A regulon, that are required for cell proliferation. Taken together, these findings prompt the design of clinical trials to examine the utility of the drugs CPX and DEF, and related agents, in anti-cancer therapy.
Materials and Methods

Immunohistochemistry
Cervical cancers were diagnosed by an experienced pathologist as squamous cell carcinoma (12 samples) or adenocarcinoma (9 samples). Tissue sections were stained for eIF5A using NIH-353 antibody (kindly provided by Dr. M.H. Park) and with Ki-67 antibody (Dako, Glostrup, Denmark) as described previously, in compliance with an IRB-approved protocol allowing anonymous use of archival, formalin-fixed, paraffinembedded biopsy material (5).
Cell culture
Cells from the American Type Culture Collection were maintained as recommended and seeded one day before treatment. CPX (Sigma-Aldrich, St. Louis, MO, USA) and DEF (Calbiochem, San Diego, CA, USA) were freshly dissolved in PBS and added to the medium for 24 to 72 hr.
Immunoblotting
Cells were lysed as described previously (19) . Proteins were assayed (Bio-Rad DC protein assay, BioRad, Hercules, CA, USA) and 1 to 20 μg samples were resolved in SDS-polyacrylamide gels. After transfer to PVDF membranes, blots were probed with primary antibody followed by horseradish peroxidase-conjugated secondary antibody Renilla plasmid using Jet-PEI (polyplus transfections). Cells were harvested 24 hrs later and expression of reporter genes analyzed (19) . 
Metabolic labeling
Two-dimensional (2D) gel electrophoresis and protein identification
HeLa cell extracts were prepared by incubation for 30 min at 4ºC in lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5% Nonidet P-40, 1 mM dithiothreitol, 0.1% SDS, 50 mM NaF, 1 mM Na orthovanadate, and protease inhibitor cocktail from Sigma-Aldrich), and analyzed in 2D gels (21) . Non-radioactive gels were fixed (40% ethanol, 10% acetic acid), stained with SYPRO ® Ruby (BioRad), and scanned on a Typhoon scanner (GE Healthcare, Piscataway, NJ, USA). Radioactive gels were dried under vacuum and exposed to autoradiography film. Spot intensities were compared visually in 3 replicate experiments for each of the analysis using spots with unchanged densities as landmarks. Spots from stained gels were processed for MALDI-TOF-TOF MS analysis ((21); Supplementary Table S1 ).
RNA extraction and real-time PCR (RT-PCR)
Total RNA was isolated using TrIzol (Invitrogen Life Technologies, Carlsbad, CA, USA).
cDNA was generated using 2 μg total RNA, random hexamers and MultiScribe reverse Mature eIF5A is required for cell growth RNA silencing was deployed to determine whether eIF5A1 over-expression is directly involved in cell proliferation. Reduction in HeLa cell number became evident 4 days after transfection with siRNA directed against eIF5A1 (si5A) compared to control siRNA (siC) (Fig. 3A, top) . Inhibition of cell proliferation correlated with the reduction in the eIF5A1 protein level (Fig. 3A, bottom) . Notably, both declined more rapidly in U2OS cells which contain less eIF5A (Fig. 3B) . Furthermore, depletion of the eIF5A modifying enzyme DOHH (Fig. 1A ) also reduced proliferation of HeLa and U2OS cells (Fig. 3A,B ).
These data indicate that hypusyl-eIF5A is critical for cell proliferation in both of these cancer cell lines.
CPX and DEF inhibit eIF5A maturation and cell proliferation
We used HeLa cells to study the effects of two drugs, CPX and DEF, which inhibit the hydroxylation of deoxyhypusyl-eIF5A by DOHH (Fig. 1A) . To monitor the drugs' action in HeLa cells, we measured hypusine formation by labeling eIF5A with Fig. S1 ). Pharmacological concentrations of CPX (30 μM) or DEF (200 μM) (10, 19) , suppressed hypusine labeling by >90% with concomitant appearance of deoxyhypusine (Fig. 3C ). Immature forms of eIF5A1 accumulated in the presence of the drugs as revealed by 2D-gel electrophoresis (Fig. 3D) . Without drug treatment, eIF5A was represented by a single predominant spot with a pI of ~5.3, corresponding to hypusyl-eIF5A (22) . Treatment with CPX or DEF led to the appearance of two spots with more acidic pI's (~5.2 and ~5.1) associated with acetylated forms of deoxyhypusyleIF5A (23) . Thus the drugs prevented the maturation of eIF5A and led to the accumulation of its immediate precursor, deoxyhypusyl-eIF5A.
Consistent with their inhibitory action on DOHH, both drugs rapidly inhibited HeLa cell proliferation (Fig. 3E) , similar to the effects of eIF5A or DOHH knockdown (Fig. 3A) . Drug-treated cells retained >93% of control viability at 24 hr, exhibited minimal apoptosis, and were arrested in the G1/S phase of the cell cycle ( Supplementary Fig.   S2 ), as reported previously, (6, 7, 15) an increase in size ( Supplementary Fig. S3 ), reminiscent of the phenotype of eIF5A-deficient yeast (24, 25) .
Modulation of protein expression by CPX and DEF
eIF5A is believed to be required for the translation of a specific class of proteins (24, 26) . Since CPX and DEF inhibit eIF5A maturation and HeLa cell proliferation, we sought to identify cellular proteins that are downstream targets of the drugs. Our strategy combined the analysis of protein levels and translation in drug-treated and untreated cells using 2D gels (Fig. 1B) . Representative gel images are presented ( Supplementary Fig. S4 ), together with sections of stained gels ( Several spots decreased in intensity as expected (e.g., spot 10), but others were observed to increase (e.g., spot 6).
We enumerated the spots in both the staining and labeling analyses that increased, decreased, or were unaltered in intensity after drug treatment (Fig. 4C) . The overwhelming preponderance of spots did not change in intensity with CPX or DEF.
Among those that did change, attention was focused on proteins whose labeling and accumulation varied in parallel (Criterion 1, Fig. 1B ). With CPX, five spots decreased and three spots increased in both types of analysis; with DEF, eight spots decreased and five increased in both types of analysis (highlighted in Fig. 4C ).
Since the drugs might impinge on cellular pathways in addition to that involving eIF5A, we further limited consideration to spots that were affected in the same way by CPX and DEF (Criterion 2). Seven spots varied coordinately with the two drugs: three increased and four decreased. It is notable that all three proteins up-regulated by CPX and nearly all (4/5) of the down-regulated proteins were shared with DEF, and that most (3/5) of the proteins up-regulated by DEF and half (4/8) of the down-regulated proteins were in common. This high degree of concordance lends confidence that the changes reflect a common pharmacological target and biochemical pathway. 
Identification of DOHH-dependent proteins
Proteins whose synthesis was affected by both drugs were eluted from unlabelled gels, analyzed by MS, and identified through database searches ( Fig. 5A; Supplementary Table S1 ). Identifications were checked by immunoblotting with specific antibodies (Criterion 3, Fig. 1B ). All were confirmed except for one up-regulated protein identified as 4-hydroxyphenylpyruvate dioxygenase (4-HPD), which could not be detected by immunoblotting (data not shown). Accordingly, 4-HPD is not included in the list of identified proteins and was not pursued further.
In addition to eIF5A1, the down-regulated proteins are heat shock protein 27 (Hsp27), DJ-1 (PARK7), and non-metastatic protein 23 (NM23), designated Group 1.
The confirmed up-regulated proteins, designated Group 2, are peroxiredoxin 2 (PRDX2) and tryptophanyl-tRNA synthetase (TrpRS).
Differential regulation of gene expression by the drugs
Immunoblotting and real-time (RT)-PCR were conducted to examine the effect of CPX and DEF on the identified proteins and their cognate mRNAs (Fig. 5B-G) .
Consistent with the action of the drugs on its post-translational modification (Fig.   3C,D) , eIF5A1 expression was not significantly affected at the total protein level (Fig.   5B, filled bars) or at the RNA level (Fig. 5B, gray bars) .
On the other hand, CPX and DEF reduced the expression of Hsp27, NM23 and DJ-1 proteins (Fig. 5C-E , filled bars), in agreement with the 2D-gel data. The degree of inhibition was ~50% with CPX and ~30% with DEF. Exceptionally, the DEF-induced reduction in the level of DJ-1 was less, possibly because the drug affects the oxidation status of this protein resulting in a change that is registered primarily in 2D gels (27) . As with eIF5A1, RT-PCR revealed no significant changes in transcript levels ( Fig. 5C-E, gray bars), indicating that the down-regulation of Group 1 proteins by the drugs is due to translational control.
The drug-induced up-regulation of PRDX2 and TrpRS was confirmed by immunoblotting (Fig. 5F,G, filled bars) . Increased expression of these proteins was accompanied by increased levels of their transcripts (Fig. 5F,G gray CAN-13-0474 stability. Interestingly, the increase in TrpRS RNA markedly exceeded that of the protein, possibly reflecting its secretion as an angiostatic factor (discussed below).
Mature eIF5A modulates Hsp27 levels and NFκB activity
To document the connection between a drug target and eIF5A modification, we selected Hsp27 for further study. Hsp27 expression is increased in high-grade intraepithelial neoplasia and squamous cell carcinoma of the cervix (28) and several other cancers. It has been directly implicated in tumor progression (29) and radio-and chemoresistance (18) . Furthermore, Hsp27 activates signaling via the transcription factor NFκB by facilitating the turnover of its inhibitor IκB (30).
Our findings with CPX and DEF (Fig. 5C ) suggested that hypusyl-eIF5A is required for elevated Hsp27 synthesis and, by extension, for NFκB-dependent transcription. To examine these inferences we depleted HeLa cells for eIF5A1 or its modifying enzymes. Immunoblotting showed that siRNA directed against eIF5A1, DHS or DOHH reduced the level of Hsp27 (Fig. 6A) , as with drug treatment (Fig. 5C) , and led to concomitant elevation of IκB as predicted (Fig. 6A) .
NFκB is essential for HIV-1 transcription (31), and CPX and DEF have been shown to inhibit expression from the HIV-1 promoter (19) . We therefore depleted HeLa cells for eIF5A1, DHS or DOHH, then transfected with an HIV-1 molecular clone expressing firefly luciferase. Reporter gene expression was inhibited by 50-60% in all cases (Fig. 6B) . Since IκB is barely detectable in control cells (Fig. 6A) , these results indicate that hypusyl-eIF5A plays an important role in regulating Hsp27 levels and NFκB activity in HeLa cells.
Discussion
The identification of two groups of target proteins sensitive to CPX and DEF has implications for the regulation of gene expression by eIF5A and for the exploration of the drugs' therapeutic potential in cancer. The cornerstone of our strategy for identifying drug targets was multiplexed 2D-gel analysis, and its reliability follows from the stipulation of three stringent criteria (Fig.   1B) . First, we considered only those proteins that responded in the same way to drug treatment when staining and labeling analyses were compared. Of the spots that increased or decreased in at least one type of analysis, ~25% (21/82) satisfied this criterion (Fig. 4C) . Second, we demanded coordinate response to CPX and DEF: seven of the remaining spots satisfied this criterion. Third, after identification by MS, we required confirmation by immunoblotting: six proteins met this final criterion (Fig. 5A) , testifying to the rigor of the overall strategy. Criterion 2, which was motivated by the likelihood that drugs can have differential side-effects, was also an effective filter. It eliminated seven spots that displayed drugspecific behavior, potential false positives that were more prevalent with DEF (6 spots) than CPX (1 spot).
Robustness of target identification
Although robust, it should also be noted that the protocol favors proteins that are relatively abundant, rapidly synthesized, and methionine/cysteine-containing. Some 300 proteins were surveyed in our gels, a sampling of <1% of the human proteome, so the target proteins identified almost certainly represent a subset of those affected by CPX and DEF.
Putative eIF5A regulon
Results presented here (Fig. 3C,D eIF5A. Although both drugs chelate iron (8, 9 ) the lowering of intracellular iron is insufficient for this activity (19)(Hanauske-Abel et al., PLOS ONE in press). Rather, they appear to fit into the enzyme's active site and abstract its iron, causing structural collapse (19) . While contributions of other pathways cannot be ruled out, the evidence points to eIF5A maturation as the primary target with far-reaching consequences including inhibition of cell proliferation resulting from the depletion of hypusyl-eIF5A and/or the accumulation of deoxyhypusyl-eIF5A (Fig. 3) .
The five newly-identified drug-sensitive proteins (Fig. 5A) are not documented cellular binding partners of eIF5A or its modifying enzymes (32) , nor do they uniformly harbor proline-rich translational signals characterized for the bacterial eIF5A homolog EF-P (Supplementary Figure S5) . Rather, they appear to be secondary drug targets regulated by hypusyl-eIF5A, as demonstrated for Hsp27 (Fig. 6 ), and they fall into two groups distinguished by both the direction of the drug response and the level at which it is exerted. Coordinate regulation of these proteins has also been observed in proteomic studies of cells treated with other agents. For example, the expression of eIF5A and NM23 is induced, and that of PRDX2 and TrpRS is repressed, after p53 activation by mitomycin C (35) . We therefore advance a model (Fig. 7) in which hypusyl-eIF5A1 modulates a regulon, or RNA operon (36) , that controls cell proliferation and possibly other processes such as the response to oxidative stress. Mechanistically, we envision that eIF5A (or possibly one or more of its target proteins) preferentially binds a subset of cellular mRNAs (37) 
Oncological implications
Like eIF5A, Group 1 proteins are associated with cell proliferation and cancer (38) (39) (40) . The best characterized is the chaperonin Hsp27, a marker for unfavorable prognosis in many human cancers and a potential therapeutic target (18, 29, 41, 42) .
Similarly, DJ-1 is highly expressed in a number of human cancers (40) . DJ-1 enhances cell survival via activation of NFκB and its silencing inhibits cell proliferation (40, 43) .
NM23 catalyzes the phosphorylation of nucleoside diphosphates and its expression is related to cell proliferative activity (44) . Although initially considered an inhibitor of metastasis, accumulating data reveal differential expression of NM23 isoforms and indicate a more complex relationship with cancer. Recent work identified NM23 as a predictor of poor survival in pancreatic cancer (45) . Furthermore, all three Group 1 proteins associate with factors that control cell shape, providing a plausible explanation for the morphological changes brought about by CPX and DEF which are possibly related to cell motility changes and metastasis (40) (Supplementary Fig. S4 ). Thus, the down-regulation of Hsp27, DJ-1 and NM23 by CPX and DEF suggests that these drugs could have a therapeutic effect in malignancies characterized by over-expression of 
and bone destruction (50) . This suggests that the enzyme prevents tumor growth in hypoxic conditions, possibly signaled by deoxyhypusyl-eIF5A, although it protects against oxidative stress in oxygen-rich environments. Therefore up-regulation of Group 2 proteins by CPX and DEF may restrain the growth of certain tumors.
In summary, we propose that eIF5A coordinates a set of genes at the level of translation (increased) and of mRNA abundance (decreased, possibly by facilitating mRNA decay). These genes define an eIF5A regulon that activates cell proliferation, and loss of eIF5A function has anti-cancer effects. The widely-used drugs CPX and DEF interfere with eIF5A post-translational modification and function, therefore qualify as candidates for exploratory oncological trials and further drug development. Extracts of cells treated with CPX or DEF were resolved in 2D gels. eIF5A was detected using BD antibody (arrows: spots with similar pI). E: Cell proliferation in HeLa cell cultures exposed to the drugs. 
